A232 EFFICACY OF TOFACITINIB FOR THE TREATMENT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS: REAL-WORLD DATA

BACKGROUND: A significant proportion of patients with moderate to severe ulcerative colitis (UC) do not respond to therapy, which includes thiopurines, glucocorticoids, and antagonists to tumour necrosis factor-α and integrin. Tofacitinib, a Janus Kinase inhibitor, has emerged as an efficacious and...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Can Assoc Gastroenterol
Main Authors: Xiao, Y, Lakatos, P L, Bourdages, R, Bitton, A, Afif, W, Kohen, R, Berberi, M, Bessissow, T
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2020
Assuntos:
Poster Presentation
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7043597/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jcag/gwz047.231
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares